Tumor cells circulating in the blood are the germ cells of breast cancer metastases. They are very rare and have not been propagated in the culture dish until now, which made research into therapy ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Although kinase inhibitors have improved outcomes for many cancer patients ... site while being more selective for FGFR3 (versus FGFR1, FGFR2, and FGFR4) to minimize off-target toxicities.

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Esophageal Cancer.

CEP-11981 is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Adenocarcinoma.